Proposed Expansion of Screening for HIV and Hepatitis C Could be Good News/Bad News Stories for Clinical Pathology Laboratories

Expanded universal screening would increase costs to the healthcare system; would the healthcare system shortchange clinical labs inadequate reimbursement for the increased number of screening tests? Separate recommendations that call for widespread, regular screening for HIV and hepatitis C can be considered to be good news/bad news stories for the clinical laboratory testing industry. That’s because the benefits in patient health are likely to incur additional costs for which the healthcare...

Frost & Sullivan Report Identifies Molecular Diagnostics as Fastest-Growing Sector of Clinical Pathology Laboratory Testing

Annual growth rates of 11% or more is predicted for molecular diagnostics in coming years Just as consolidation and acquisitions reshaped the in vitro diagnostics (IVD) manufacturing industry and concentrated market share among just a handful of multi-billion dollar IVD giants, a similar consolidation can be seen in the molecular diagnostics sector. Today it is estimated that just nine global companies control 75% of the molecular diagnostics market. That market concentration means clinical...
;